The majority of children and adolescents with acute myeloid leukemia (AML) are candidates for diphtheria fusion toxin therapy.

被引：0
|
作者：
Hall, PD
Razzouk, BI
McLean, T
Willoughby, TE
Frankel, AE
机构：
[1] Med Univ S Carolina, Charleston, SC 29425 USA
[2] St Jude Childrens Res Hosp, Memphis, TN 38105 USA
[3] Wake Forest Univ, Ctr Comprehens Canc, Winston Salem, NC 27109 USA
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4563
引用
收藏
页码：213B / 213B
页数：1
相关论文
共 50 条
  • [1] Selective cytotoxicity of diphtheria toxin-interleukin 3 fusion protein for acute myeloid leukemia (AML) stem cells
    Feuring-Buske, M
    Frankel, AE
    Gerhard, B
    Hogge, DE
    EXPERIMENTAL HEMATOLOGY, 2000, 28 (07) : 81 - 81
  • [2] Phase I trial of a novel diphtheria toxin/GM-CSF fusion protein in refractory or relapsed acute myeloid leukemia (AML).
    Frankel, AE
    Powell, BL
    Hall, PD
    Mone, AP
    Molnar, I
    Kreitman, RJ
    BLOOD, 2001, 98 (11) : 722A - 722A
  • [3] Acute myeloid leukemia (AML) in older women after adjuvant breast cancer therapy.
    Patt, D. A.
    Duan, Z.
    Hortobagyi, G.
    Giordano, S. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 17S - 17S
  • [4] A diphtheria toxin-interleukin-3 fusion protein is cytotoxic to acute myeloid leukemia (AML) stem cells but spares normal progenitors.
    Feuring-Buske, M
    Frankel, AE
    Gerhard, B
    Hogge, DE
    BLOOD, 2000, 96 (11) : 118A - 118A
  • [5] Mylotarg in the therapy of acute myeloid leukemia (AML).
    Weber-Nordt, RM
    Lenze, A
    Gottschling, S
    Steiger, S
    Ho, AD
    BLOOD, 2001, 98 (11) : 225B - 225B
  • [6] Diptheria toxin-interleukin 3 fusion protein therapy of patients with elderly or relapsed/refractory acute myeloid leukemia (AML).
    Frankel, A. E.
    Weir, M. A.
    Hall, P. D.
    Hogge, D. E.
    Rizzieri, D. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 354S - 354S
  • [7] OUTCOME OF POSTINDUCTION THERAPY IN 824 CHILDREN WITH ACUTE MYELOID-LEUKEMIA (AML)
    FEIG, SA
    NESBIT, M
    LAMPKIN, B
    LANGE, B
    WOODS, W
    LEE, JW
    HAMMOND, D
    EXPERIMENTAL HEMATOLOGY, 1993, 21 (08) : 1020 - 1020
  • [8] Acute myeloid leukemia (AML) in the elderly: Aggressive versus non aggressive therapy. A report of the gimema archive of adult acute leukemia
    Pulsoni, A
    Latagliata, R
    Tosti, ME
    Candoni, A
    Carella, AM
    Cerri, R
    Di Bona, E
    Fabris, P
    Ferrara, F
    Invernizzi, R
    Martino, B
    Melpignano, A
    Miceli, S
    Miraglia, E
    Monaco, M
    Pagano, L
    Rocchi, L
    Visani, G
    Mele, A
    Mandeli, F
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 102 (01) : 224 - 224
  • [9] The majority of adult patients with acute myeloid leukemia (AML) have low to undetectable concentrations of antibodies against DTGM, a novel fusion toxin consisting of a truncated diphtheria toxin (DT) linked to human granulocyte macrophage colony stimulating factor (GM).
    Hall, PD
    Virella, G
    Beckham, W
    Frankel, AE
    BLOOD, 1999, 94 (10) : 64A - 64A
  • [10] OUTCOMES OF SALVAGE CHEMOTHERAPY REGIMENS IN CHILDREN AND ADOLESCENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML)
    Tak, Himangi
    Trivedi, Maharshi
    Joshi, Nitin
    Panchal, Harsha
    PEDIATRIC BLOOD & CANCER, 2023, 70 : S553 - S553
12345